Lemborexant

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Lemborexant
Lemborexant.svg
Clinical data
Synonyms E-2006
ATC code
  • None
Legal status
Legal status
  • Experimental drug
Identifiers
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
Formula C22H20F2N4O2
Molar mass 410.417 g/mol
3D model (JSmol)

Lemborexant (INN) (code name E-2006) is a dual antagonist of the orexin OX1 and OX2 receptors which is under development by Eisai for the treatment of insomnia.[1] [2][3] In June 2016, Eisai initiated phase 3 clinical trials which are currently underway in the US, France, Germany, Italy, Japan, Poland, Spain and the UK, and are expected to extend to Canada. [4]

See also[edit]

References[edit]

  1. ^ Christopher, John A (2014). "Small-molecule antagonists of the orexin receptors". Pharmaceutical Patent Analyst. 3 (6): 625–638. doi:10.4155/ppa.14.46. ISSN 2046-8954. 
  2. ^ Cristoph Boss, Catherine Ross (2015). "Recent Trends in Orexin Research – 2010 to 2015". ScienceDirect. doi:10.1016/j.bmcl.2015.05.012. 
  3. ^ Boss, Christoph (2014). "Orexin receptor antagonists – a patent review (2010 to August 2014)". Expert Opinion on Therapeutic Patents. 24 (12): 1367–1381. doi:10.1517/13543776.2014.978859. ISSN 1354-3776. 
  4. ^ "Lemborexant – SPS - Specialist Pharmacy Service – The first stop for professional medicines advice". www.sps.nhs.uk. Retrieved 2017-11-05. 

External links[edit]